




SHAREABLE PDF



AGORA
CORRESPONDENCE

Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?

Guy Meyer¹ and Stavros Konstantinides ^{2,3}

Affiliations: ¹Division of respiratory disease, APHP Centre; Université Paris Descartes; Université de Paris, Paris, France. ²Center for Thrombosis and Haemostasis, University Medical Centre Mainz, Mainz, Germany. ³Dept of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece.

Correspondence: Guy Meyer, Service de Pneumologie, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France. E-mail: guy.meyer@aphp.fr



@ERSpublications

For patients with first pulmonary embolism secondary to a major transient/reversible risk factor, discontinuation of therapeutic oral anticoagulation is recommended after 3 months
<http://bit.ly/2Pp68Ti>

Cite this article as: Meyer G, Konstantinides S. Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?. *Eur Respir J* 2020; 55: 1902323 [<https://doi.org/10.1183/13993003.02323-2019>].

This single-page version can be shared freely online.

From the authors:

We would like to thank H. Slabbynck and co-workers for their interest in the 2019 European Society of Cardiology/European Respiratory Society guidelines on the diagnosis and management of acute pulmonary embolism (PE), and for their interesting comment on the treatment duration of patients with a high-risk PE secondary to a major transient/reversible risk factor.